With CRISPR gene editing technology continuing to evolve, many ethical arguments have arisen about its use in humans due to its potential for serious misuse. However, some have argued that it is also unethical not to harness the power of this technology given the enormous potential benefit it poses to humankind. Considering the range of applications of CRISPR and the ease with which it can be applied, it is critical for us to put appropriate regulatory processes and policies in place to mitigate the associated risks.
CRISPR/Cas9 or, as its commonly known, CRISPR is a gene editing technology developed in 2011 that allows researchers to edit plant, animal, and human genes with ease and efficiency. Research leveraging CRISPR has led to new, important findings, such as potential new ways of treating diseases like Alzheimers one of many discoveries made by the research group led by Gerold Schmitt-Ulms, a professor at U of Ts Department of Laboratory Medicine & Pathobiology and a researcher at the Tanz Centre for Research in Neurodegenerative Diseases.
Using CRISPR as a tool to understand and treat diseases
Schmitt-Ulms research group is using CRISPR to generate cell models in order to better understand the pathology of phenomena like Alzheimers disease. In an email to The Varsity, Schmitt-Ulms wrote that his group used CRISPR to introduce mutations into human cells that are known to cause inherited versions of the neurodegenerative diseases [they] study.
Studies in cell and animal models represent critical steps toward gaining the insights necessary to transform these tools into medicines, he added.
The hope among many researchers is that CRISPR could lead to large-scale applications for human health, agriculture, and the conservation of endangered species. Given its ability to easily edit any gene, CRISPR could be used to treat things such as HIV, hemophilia, cancer, cystic fibrosis, and infertility, just to name a few. It could even allow humans to receive organs from other species in life-saving organ transplants.
CRISPR has been described as having the potential to revolutionize disease treatment. In addition to treating diseases in humans, it has the potential to eradicate diseases such as malaria by the genetic modification of the species that are carriers of these diseases. It could also be used to protect endangered species or to fortify crops to improve their nutritional content. However, there are concerns that widespread use of the technology could lead to unpredictable consequences, including the creation of designer babies and irreversible disruption to ecosystems.
Ethical concerns of using the technology
One controversial application of CRISPR is its use in human embryos. Presently, if someone edits the human genome in any way that can be inherited, even in a lab setting, its punishable by up to 10 years in prison in Canada one of the most restrictive gene editing laws in the world. The law does not prevent gene editing on all human cells, but only on so-called germ line cells such as embryonic cells that could be passed on through reproduction. Some researchers have been calling for the Canadian government to modify this law to allow research on human reproduction and embryo development with more ease and efficiency.
While Schmitt-Ulms agrees that CRISPR has made it easier to study just about any disease, he emphasized that we are not ready to bring the technology to humans just yet. The main hurdle to human applications are the challenges associated with delivering this technology safely and ethically, he wrote.
Many of the ethical concerns surrounding the use of germ line cells for research have existed before CRISPR, since they are primarily related to controversy regarding the status of a human embryo. Another unknown factor is whether modifications made to germ lines will persist in future generations, which raises major ethical concerns. Even though we are not at the point where CRISPR can be applied to humans, technological advancements like this can evolve quickly gene editing is already part of our society.
The combination of in vitro sterilization and selection of embryos can already today prevent a subset of severe genetic diseases, including inherited forms of prion diseases that my group studies, Schmitt-Ulms wrote.
Humans have been dramatically altering the genetic realities on this planet ever since they started selecting species for farming, and gene-modified foods were introduced decades ago.
However, due to the scale and speed at which gene editing can be done using CRISPR, he recognizes that unethical applications of the technology [pose] indeed considerable risks.
For example, there could be unintended effects of gene editing in humans because scientists dont yet know the function of every gene in the human genome. Additionally, there are concerns surrounding the development of designer babies with specific physical or psychological features or qualities which could drastically exacerbate societal inequities. Even more insidiously, gene editing could be used for eugenics, which involves encouraging gene selection for certain superior traits in human populations.
Another potential concern is the unpredictable consequences on ecosystems and the environment that could arise from using CRISPR to modify other species and crops. The application of CRISPR for crop modification could be extremely useful for addressing famine in certain countries, but if measures arent taken to ensure equitable access, it could similarly exacerbate inequities around the globe.
CRISPR needs responsible regulation
In some communities, researchers are already conducting gene editing experiments on species that are carriers of diseases transmissible to humans. They are mitigating the risks associated with this type of research by developing safety features to control or reverse genetic modifications among a species in case unintended consequences arise.
The ways CRISPR could be misused and abused are serious and need to be addressed. However, the enormous potential benefits of this technology cannot be ignored. As CRISPR continues to evolve, governmental policies will also have to evolve, and governments should consider the social, environmental, and health risks associated with each application of the technology.
As with any risk management, the strictness of regulations need to scale with the risk an activity poses. Not all CRISPR applications are equally dangerous, Schmitt-Ulms emphasized.
There is also a risk associated with failing to leverage this technology in the future for example, there are a lot of diseases that could be treated with the help of CRISPR.
Researchers are continuing to study and improve CRISPR at a fast pace with the hope of eventually bringing its advancements to humans. Schmitt-Ulms advocates for devoting additional time and resources to developing regulatory frameworks for the safe use of this technology. Many researchers have expressed support for the establishment of an international organization that would provide guidance about the ethical use of gene editing.
As with any new technology, a risk-benefit analysis needs to be done for each new potential use of CRISPR. We as a society need to decide what we are and are not willing to accept.
As Schmitt-Ulms pointed out, humanity has developed powerful technologies that can be directed toward nefarious purposes before. These types of scientific advances need to be paralleled by broad public debate on the safe and ethical use of novel technologies.
Original post:
Opinion: Gene editing can be leveraged for the greater good with appropriate regulations - Varsity
- IOM not webcast today. Why Not? - November 8th, 2009 [November 8th, 2009]
- National Academies skeptical at Best. - November 8th, 2009 [November 8th, 2009]
- Some Confusion Exists - November 8th, 2009 [November 8th, 2009]
- Why DTC Genomics IS Medicine. - November 8th, 2009 [November 8th, 2009]
- First Mari, Now Linda. Who's next? - November 8th, 2009 [November 8th, 2009]
- Is it true? - November 8th, 2009 [November 8th, 2009]
- Re-Reviewing the National Academies - November 8th, 2009 [November 8th, 2009]
- The problem with nonclinicians....... - November 8th, 2009 [November 8th, 2009]
- Crazy Night of Emails to Government - November 8th, 2009 [November 8th, 2009]
- Adrienne Carlson's Personalized Medicine. - November 8th, 2009 [November 8th, 2009]
- Tell Me, How do you feel now? Sherpa's RX - November 8th, 2009 [November 8th, 2009]
- This Just In. 23andMe to go to GPs. I love my readers!! - November 8th, 2009 [November 8th, 2009]
- Sorry so long away - November 8th, 2009 [November 8th, 2009]
- 2D6 Rears its ugly head..... - November 8th, 2009 [November 8th, 2009]
- Ok, Fine, Back to Plavix - November 8th, 2009 [November 8th, 2009]
- Kaiser a protoype for Collins' Aim - November 8th, 2009 [November 8th, 2009]
- A few months late to the party.... - November 8th, 2009 [November 8th, 2009]
- Stated Another Way....... - November 8th, 2009 [November 8th, 2009]
- Excuse Me? Harvard and Navigenics? WTF? - November 8th, 2009 [November 8th, 2009]
- Follow up to Yesterday's WTF? Harvard, Navi? and Pfizer??? - November 8th, 2009 [November 8th, 2009]
- Did you get your kit? Thanks Dr. Rob from MedCo - November 8th, 2009 [November 8th, 2009]
- Gluco...Wha? Parkinson's Disease and Glucocerebrosidase mutations. - November 8th, 2009 [November 8th, 2009]
- Away and now back, What did I miss???? 23andme layoffs? Selling Genomes for cheap up next! - November 8th, 2009 [November 8th, 2009]
- Change IS Needed. I agree with William, sometimes. - November 8th, 2009 [November 8th, 2009]
- Good Enough Science? Apparently so at 23andme - November 8th, 2009 [November 8th, 2009]
- Long QT Syndrome, location matters - December 13th, 2009 [December 13th, 2009]
- Congratulations Generation Health. Nice pick up! - December 13th, 2009 [December 13th, 2009]
- An argument 23andSerge can't win...23andme but not medicine - December 13th, 2009 [December 13th, 2009]
- Stop. Breathe. Repeat. An analysis of the direction of DTC Genomics Field. - December 13th, 2009 [December 13th, 2009]
- Hey DTC genomics, Stay Private, Stay Alive, Go Public and Die - December 13th, 2009 [December 13th, 2009]
- You can't have it both way. Either scared your genome is sold off or not. - December 13th, 2009 [December 13th, 2009]
- 15 Days Away Gives Time for Perspective. - December 13th, 2009 [December 13th, 2009]
- What about the SACGHS registry? Another missed opportunity? - December 13th, 2009 [December 13th, 2009]
- AJHG is in and my Favorite Muin is in it! But He Is NOT the Father! - December 13th, 2009 [December 13th, 2009]
- Navigenics for 23andMe prices? - December 18th, 2009 [December 18th, 2009]
- Lp(a) Maybe there's something there that wasn't there before? - December 24th, 2009 [December 24th, 2009]
- Another Year, Another Bankruptcy - December 31st, 2009 [December 31st, 2009]
- 5 Technologies going bye bye in this decade? - January 6th, 2010 [January 6th, 2010]
- Hackers, HITECH and HIPAA in DTC Genomics, Oh My! - January 7th, 2010 [January 7th, 2010]
- Personal Genomics Flop.....big Belly Flop! - January 8th, 2010 [January 8th, 2010]
- Gotta Love It. Even the daycare....... - January 11th, 2010 [January 11th, 2010]
- Congratulations Navigenics. You ARE a clinical lab! Uh-Oh... - January 12th, 2010 [January 12th, 2010]
- CETP, Jewish Centenarians and Alzheimers - January 14th, 2010 [January 14th, 2010]
- Enter the "Not" DTC Genomics Rep - January 17th, 2010 [January 17th, 2010]
- Why Dr. Vanier's Navigenics appointment is good for PM - January 22nd, 2010 [January 22nd, 2010]
- Holy Crap! MedCo Follows in CVS footsteps - February 3rd, 2010 [February 3rd, 2010]
- FDA, Warfarin, still not as sexy to me. - February 5th, 2010 [February 5th, 2010]
- Hype, Hype, Hype from a single study. - February 11th, 2010 [February 11th, 2010]
- I love my readers, even Renata M! - February 17th, 2010 [February 17th, 2010]
- How can insurers use DTC genomics to profile? - February 17th, 2010 [February 17th, 2010]
- 9p21.....ahem. Paynter et.al. Smackdown. Again. - February 18th, 2010 [February 18th, 2010]
- Hey! It's Pete Hulick! Are you Going to GET? - February 19th, 2010 [February 19th, 2010]
- I was wrong......AHEM - February 28th, 2010 [February 28th, 2010]
- G2C2, finally a tool for genomic education! - March 2nd, 2010 [March 2nd, 2010]
- Just 4 million? What 23andMe is worth. - March 5th, 2010 [March 5th, 2010]
- What a difference a year makes - March 9th, 2010 [March 9th, 2010]
- ........DTC Genomic Medicine? - March 12th, 2010 [March 12th, 2010]
- The FDA, 2c19 and the ACC - March 13th, 2010 [March 13th, 2010]
- The problem with Comparative Whole Genomics...... - March 13th, 2010 [March 13th, 2010]
- BRCA testing by 23andME is the same as Myriad Genetics. - March 15th, 2010 [March 15th, 2010]
- The Argument Against DTC Genomics Marketing and such - March 16th, 2010 [March 16th, 2010]
- A moment of Clarity. Some DTCG is not bad. - March 18th, 2010 [March 18th, 2010]
- SNPs for breast cancer risk? It Depends. - March 18th, 2010 [March 18th, 2010]
- How can MDVIP use Navigenics Test for Medicine? - March 18th, 2010 [March 18th, 2010]
- Why did P&G invest in Navigenics? - March 23rd, 2010 [March 23rd, 2010]
- PGx in DTCG? Doesn't stand up to Useful testing. - March 25th, 2010 [March 25th, 2010]
- End of Gene Patents? - March 29th, 2010 [March 29th, 2010]
- Sherpa Accepting Chief Medical Officership - April 3rd, 2010 [April 3rd, 2010]
- The Rumors of My Death........ - April 20th, 2010 [April 20th, 2010]
- Happy DNA Day! - April 25th, 2010 [April 25th, 2010]
- 99 USD, DNA day and patient letters - April 25th, 2010 [April 25th, 2010]
- 2C19, Navigenics and Clinical Reality. - May 1st, 2010 [May 1st, 2010]
- Coriell Personalized Medicine Collaborative rising - May 7th, 2010 [May 7th, 2010]
- Personal Genomes in Clinical Care. Quake paper is a waste! - May 11th, 2010 [May 11th, 2010]
- Personal Genomes in Clinical Care. Quake paper Falls Short! - May 13th, 2010 [May 13th, 2010]
- Last post edited by Drew - May 13th, 2010 [May 13th, 2010]
- GateKeeper? FCUK U! - May 13th, 2010 [May 13th, 2010]
- GateKeeper? F! U! - May 15th, 2010 [May 15th, 2010]
- Potential of genomic medicine, LOST - May 19th, 2010 [May 19th, 2010]
- How Bad Can a House Investigation be for DTC Genomics? - May 20th, 2010 [May 20th, 2010]